Verona Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Verona Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
0.4%
Buyback Yield
| Total Shareholder Yield | 0.4% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Verona Pharma: A Post FDA Approval Analysis
Sep 10Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?
Apr 26Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Jan 26Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?
Oct 12Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Jun 27Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?
Mar 10Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?
Dec 02Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%
Feb 02Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19
Jan 14Verona Pharma EPS beats by $0.15
Oct 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if VRNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VRNA's dividend payments have been increasing.
Dividend Yield vs Market
| Verona Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (VRNA) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (VRNA) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate VRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate VRNA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VRNA has not reported any payouts.